Clinical Trial Update: The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial [Phase 2]

View source ↗

Summary

An open Phase 2 trial evaluating PSMA-Lu177 for adenoid cystic carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma

Drugs mentioned

• PSMA-Lu177 (Lutetium-177 labeled PSMA-targeted radioligand)

Snippet

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | Conditions: Adenoid Cystic Carcinoma | Phase 2 | Status: WITHDRAWN